BALTIMORE, July 29, 2010 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has initiated research coverage of NeoStem, Inc. (NYSE Amex:NBS), a pharmaceutical firm engaged in stem cell therapies and generic pharmaceuticals in China.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines milestone events that he believes will serve as catalysts for the Company's shares.
"We view NeoStem as a stock that offers a rare opportunity to participate in two of the most exciting and fastest growing segments in all of the health care space: stem cells and the domestic pharmaceutical industry in China. The Company is a pioneer in the collection and storage of adult stem cells, a leader in stem cell therapy development and is even engaged in joint ventures with the Vatican. NeoStem presents great value and home run potential with its business model and products and services under development."
To view a summary of the report or download the report in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap stock market research reports and weekly newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer. To download our research or for more information, visit www.goldmanresearch.com.
About NeoStem, Inc.: NeoStem, Inc. (NYSE Amex:NBS) is an international biopharmaceutical company engaged in adult stem cell collection and storage, the development of stem cell-based therapies, and generic pharmaceuticals in China. NeoStem's network of adult stem cell collection centers in the U.S. and China enable people to donate and store their own stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ technology which has shown to have several physical characteristics typically found in embryonic stem cells. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China.
For more information and disclosures, visit www.neostem.com